Cantor Fitzgerald Brokers Lift Earnings Estimates for TVRD

Key Points

• Analysts at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimate for Tvardi Therapeutics from ($2.01) to ($1.91), while also predicting FY2026 EPS of ($2.28).
• Several firms have recently adjusted their ratings on Tvardi Therapeutics, with Piper Sandler downgrading to "neutral" and BTIG Research lowering the price target from $55.00 to $15.00.
• Tvardi Therapeutics shares opened at $6.64, experiencing significant price fluctuations with a 12-month high of $43.65 and a low of $5.65.

Tvardi Therapeutics, Inc. (NASDAQ:TVRD - Free Report) - Analysts at Cantor Fitzgerald increased their FY2025 EPS estimates for Tvardi Therapeutics in a research note issued to investors on Monday, October 13th. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the company will post earnings of ($1.91) per share for the year, up from their prior forecast of ($2.01). Cantor Fitzgerald currently has a "Neutral" rating on the stock. Cantor Fitzgerald also issued estimates for Tvardi Therapeutics' FY2026 earnings at ($2.28) EPS.

Other analysts have also recently issued research reports about the stock. Piper Sandler cut shares of Tvardi Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Monday. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Tvardi Therapeutics in a research note on Tuesday. BTIG Research dropped their price objective on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a "buy" rating for the company in a research note on Monday. Raymond James Financial cut shares of Tvardi Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Tuesday. Finally, Barclays set a $5.00 price objective on shares of Tvardi Therapeutics and gave the company an "equal weight" rating in a research note on Monday. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Tvardi Therapeutics currently has an average rating of "Hold" and an average target price of $55.50.

Tvardi Therapeutics Price Performance

Shares of NASDAQ TVRD opened at $6.64 on Thursday. Tvardi Therapeutics has a 12-month low of $5.65 and a 12-month high of $43.65. The company's 50-day simple moving average is $30.90.

Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.49). Tvardi Therapeutics had a negative net margin of 678.79% and a negative return on equity of 565.83%.

Hedge Funds Weigh In On Tvardi Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Slate Path Capital LP purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $16,427,000. 683 Capital Management LLC purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $4,107,000. Geode Capital Management LLC purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $2,617,000. Marshall Wace LLP purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $583,000. Finally, Bank of America Corp DE purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $399,000. Hedge funds and other institutional investors own 44.66% of the company's stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.